CLINICAL_TRIALS
trial_result
· 2019-03-20
Clinical Trial Update: Phase III Study of MLN0002 (300 mg) in the Treatment of Ulcerative Colitis [Phase 3]
Summary
Phase III study of MLN0002 (300 mg) in ulcerative colitis has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Takeda | Conditions: Ulcerative Colitis | Phase 3 | Status: COMPLETED | Results posted: 2019-03-20